INTRODUCTION
Chymostatin, a tetrapeptide analogue from culture filtrates of Streptomyces hygroscopicus and Streptomyces lavendulae, is a powerful inhibitor of a number of proteinases including the serine proteinases, chymotrypsin and Streptomyces griseus proteinase A, and several cysteine proteinases (Umezawa et al., 1979) . The inhibitor has several unusual structural features (Fig. 1) . A C-terminal aldehyde group is essential for inhibitory activity via formation of a hemiacetal or hemithioacetal adduct with the nucleophilic hydroxy or thiol group of the serine and cysteine proteinases. Secondly, a capreomycidine residue occupies the position that would be defined as the P3 residue in a normal peptide, using the nomenclature of Schechter & Berger (1967) . Additionally, a ureido linkage reverses the chain direction (Fig. 1). Although the main determinant of inhibitory activity is the C-terminal aldehydic group, it is not clear whether the other residues in chymostatin make major or minor contributions to the inhibitory potential of this molecule.
The chymostatin-Streptomyces griseus proteinase A (SGPA) complex has been analysed by X-ray crystallography (Delbaere & Brayer, 1985) , and the main interactions between the proteinase and inhibitor have been identified. A covalent hemiacetal bond is formed between the active-site Ser-195 and the C-terminal aldehyde moiety, which contributes to the binding by its resemblance to the tetrahedral intermediate in proteolytic catalysis (Gorenstein & Shah, 1982) . Secondly, the C-terminal phenylalanine residue of the inhibitor is bound to the primary specificity pocket of the enzyme. Thirdly, there is hydrophobic binding of the penultimate leucine to the small P2 pocket. Finally, hydrogenbonding between the main chain of the inhibitor and part of the main chain of the enzyme stabilizes the interaction (Segal, 1972; Baumann et al., 1973; Bauer et al., 1976; Moffit & Means, 1978) In common with several of the microbial proteinase inhibitors, chymostatin is relatively non-toxic and is well tolerated in a number of intact cell systems. It is an inhibitor of both the lysosomal and non-lysosomal pathways of protein degradation and can decrease rates of proteolysis in muscle fibres and hepatocytes (Grinde et al., 1983; Mulligan et al., 1985; Place et al., 1987) . Chymostatin is an inhibitor of the cytosolic Ca2l-dependent proteinase calpain (Hopgood et al., 1989) , and some of the activities of the cytosolic multicatalytic proteinases (Mason, 1990; Dick et al., 1991) that may play an essential role in antigen presentation (Ortiz-Navarette et al., 1991; Martinez & Monaco, 1991; Kelly et al., 1991) and in the degradation of ubiquitin-protein conjugates (Rivett, 1989) .
We prepared a series of chymostatin analogues (Galpin et al., 1984 ; Fig. 1 ). The C-terminal Phe-aldehyde was retained, but the remainder of the structure was modified. The hydrophobic phenylalanine residue would be expected to bind to the S1 pocket, in accordance with the known primary-sequence specificities of chymotrypsin and SGPA, favouring aromatic groups (phenylalanine, tyrosine, tryptophan) in P1 (Matthews et al., 1967; Steitz et al., 1969; Dupaix et al., 1970 (Norman, 1989) .
Purification of SGPA SGPA was purified from Pronase by the method of Narahashi (1970) . Pronase is a partially purified isolate obtained from the culture broth of Streptomyces griseus K-1. It is a mixture of proteinases and as such is non-specific. The crude enzyme preparation was purified by two ion-exchange steps and the procedure was monitored by A280 to detect protein, and by assay of proteolytic activity against the substrate SAAPFNA (Juravsek et al., 1971; Bauer et al., 1976) .
Assay of chymotrypsin
A stock of chymotrypsin (1 #M) was prepared in 1 mM-HCl by using the absorption coefficient £280 = 50000cm-l M-1. This solution (20 ,l) was incubated for 10 min at 25°C with 20 ,1 of dimethyl sulphoxide as control or with 20 ,l of inhibitor/ dimethyl sulphoxide solution, in 1 ml of 50 mM-Hepes/l0 mmCaC12 at pH 8.0 in a spectrophotometer cuvette. Dimethyl sulphoxide alone did not affect the rate of hydrolysis. The reaction was started by addition of one of five dilutions of substrate (SAAPFNA; Delmar et al., 1979) 
Molecular modelling
All models were built from initial crystal structures by using the program QUANTA ver 3.0 by Polygen (Europe) Ltd. (Reading, Berks., U.K.) run on a Silicon-Graphics 4D/20G Personal Iris workstation.
RESULTS AND DISCUSSION
Seventeen inhibitors were tested, along with chymostatin ( Fig.  1) . For all inhibitors, kinetic constants were determined at five substrate concentrations and four inhibitor concentrations; each velocity measurement was made in duplicate or triplicate. Representative data for a relatively good inhibitor (chymostatin inhibition of SGPA) and a relatively weak inhibitor (Z-Nle-LeuPhe-H inhibition of chymotrypsin) are shown in Fig. 2 . The data are plotted with superimposed fitted hyperbolic curves derived from non-linear curve fitting. Similar-quality data were derived from all other inhibitors (results not shown). Except for chymostatin inhibition of chymotrypsin, the data are clearly indicative of pure competitive inhibition. This is illustrated by plots of [SAAPFNAl (#uM) [substrate]/velocity as a function of inhibitor concentration at each of the five substrate concentrations (Fig. 3) Similar behaviour is seen with Z-Nle-Leu-Phe-H (K1 = 0.8 /LM) and the corresponding amide or alcohol (K1 = 14.7,UM and 13.6 /LM respectively). Semicarbazones, which also bind cysteine proteinases more weakly, are effective affinity ligands (Rich et al., 1986) . The tripeptide aldehydes are at least an order of magnitude more active than the dipeptides. The difference in activity between the P3 norleucyl-tripeptides and the dipeptides may be attributable to main-chain hydrogen-bonding between the CO and NH groups of the third inhibitor residue (norleucine) and the peptide backbone of the enzyme. This is inferred from results obtained by Moffitt & Means (1978) and Segal (1972) that showed a difference in binding constants of a similar magnitude between P3 glycyl-tripeptide and -dipeptide substrates, indicating the lack of any contribution to binding from the P3 side-chain residue. However, replacement of norleucine in P3 by arginine leads to a small but significant increase in binding, when the P2 group is either leucine or isoleucine. Interestingly, this does not seem to be the case when the P2 residue is valine. The data for Z-Arg-Leu-Phe-imidate and Z-Asp-Leu-Phe-imidate show that aspartic acid in the P3 position is detrimental to inhibition, indicating that the enhanced binding on replacement of a norleucine by arginine in P3 is probably not due to simple hydrophilicity of the arginine group but that side-chain length or basicity may be responsible. A study of lysine or glutamate derivatives should be informative in this context. Finally, the ZNle-Leu-cyc-o-Tyr structure, although reasonably inhibitory (Ki = 7/M), is not much superior to Z-Nle-Leu-Phe-alcohol or Z-Nle-Leu-Phe-amide. Constraint of the carbonyl group by incorporation into a cyclic structure did not seem to favour binding or inhibition.
Chymostatin behaves as a significantly more potent inhibitor of chymotrypsin than does Z-Arg-Leu-Phe-H, the closest structural analogue. Moreover, the inhibition data are consistent with Vol. 286 The crystallographic structure of chymostatin bound to SGPA was used to generate the conformation of chymostatin and as a basis on which to build the structure of Z-Arg-Leu-Phe-H. For the remaining three structures, the inhibitor was docked into the active site of the corresponding proteinase and minimized. (a) Chymostatin bound to chymotrypsin; (b) Z-Arg-Leu-Phe-H bound to chymotrypsin; (c) chymostatin bound to SGPA; (d) Z-Arg-Leu-Phe-H bound to SGPA. (c) is derived from a crystallographic study; the other three are generated by molecular mechanics. The inhibitor structure is highlighted in bold, and Lys-175 in chymotrypsin is indicated by a dashed line. chymostatin being a mixed inhibitor, whereas Z-Arg-Leu-Phe-H is purely competitive. By contrast, the same two inhibitors are equally potent against SGPA and both are pure competitive inhibitors of this enzyme (Ki = 0.24 ftM and 0.20 ItM respectively).
This implies that there are interactions between chymostatin and chymotrypsin that enhance the binding and which are not characteristic of binding to SGPA. Whatever is responsible for the strong chymostatin-chymotrypsin interaction over and above that present in Z-Arg-Leu-Phe-H-chymotrypsin must result from a feature(s) unique to chymostatin (i.e. missing from Z-Arg-LeuPhe-H) interacting with corresponding structural feature(s) on the chymotrypsin molecule. This additional interaction must be unique to chymotrypsin, as chymostatin is no better an inhibitor of SGPA than is Z-Arg-Leu-Phe-H. Initial docking studies suggested that a site of this interaction could be the 170-175 helical loop on chymotrypsin and the N-terminal phenylalanine residue on chymostatin; these are in close proximity in the modelled chymostatin-chymotrypsin structure. The loop is not present in SGPA, and the C-terminal phenylalanine residue, with its carboxylate group, is absent from Z-Arg-Leu-Phe-H. All the other binding sites from SI to S3 appear to be similar for both enzymes. In both enzymes, SI is a deep hydrophobic pocket of optimal size for binding six-membered aromatic rings, S2 is a shallow hydrophobic pocket capable of accepting isopropyl or similar-sized side chains and S3 is primarily exposed to solvent. Main-chain hydrogen-bonding between enzyme and ligand is 1992 also similar for both SGPA and chymotrypsin binding of tripeptides.
Loop 170-175 is a relatively basic peptide, the sequence being Lys(169)-Lys(170)-Tyr(171)-Trp(172)-Gly(173)-Thr(174)-Lys(l75)-Ile(176)-Lys(l77), which might suggest an interaction between one or more of these basic residues with the distal carboxylate group of chymostatin. Although this would be mainly a surface interaction surrounded by water, it is the most likely explanation for the increased strength of binding. This is supported by studies showing that acidic N-terminal groups favour substrate binding and acylation in substrates of similar length to these inhibitors (Delmar et al., 1979; Fischer et al., 1984; Tozser et al., 1986) .
To investigate the binding of chymostatin to chymotrypsin further, a docking study was performed, using published X-ray structures and starting from the co-ordinates of chymotrypsin (Tsukada & Blow, 1985; Tulinsky & Blevins, 1987; 4CHA, 6CHA, October 1990 version) and the co-ordinates of SGPAchymostatin (Delbaere & Brayer, 1985; ISGC, October 1990 version) obtained from the Protein Data Bank (Bernstein et al., 1977; Abola et al., 1987) . The structure of chymostatin was excised from chymostatin-SGPA and docked into the crystal structure of chymotrypsin. It was not necessary to modify the enzyme in order to dock the P1, P2 and P3 side chains and the main chain of the inhibitor to chymotrypsin. The P1-S1 interaction and the hemiacetal were modelled first, avoiding close contacts. The P2 -and P3 groups were then fitted, again using the chymostatin-SGPA crystal structure as a guide. However, the P4 side chain could not adopt the same conformation as in chymostatin-SGPA owing to the presence of Trp-172 blocking this position. Rotation about the CA-CB and CB-CG bonds of the P4 phenylalanine side chain brought the benzene ring up and forward away from close contacts. This was aided by a small rotation of the CB-CG bond of Trp-172. There was no obstruction to this movement. This structure was refined by energy minimization by using the molecular mechanics package, CHARMm (version 21.2; Brooks et al., 1983) with the commercial parameter set PARM30.PRM. [residues 193 and 195 N-H (2.5 + 0.3 A)] (scale 20.0, temperature 300 K) were necessary to maintain the docked structure in the initial stages of the minimization. These constraints were gradually decreased to zero during the minimization. The protein was held in place in the early stages using a force constant of 84 kJ/mol per A but this was also gradually decreased to zero during the minimization. After 500 steps of unconstrained Adopted Basis-set NewtonRaphson (ABNR) minimization using a dielectric permittivity e = r (the interatomic distance in A), and a shifted non-bonded cut-off of 12.0 A and updating the non-bonded list every 20 steps, the energy of the molecule was -24229.4 kJ and the derivative of the energy was less than 2.1 kJ/mol per A.
This structure was modified to give Z-Arg-Leu-Phe-Hchymotrypsin which was then minimized. In both enzymes the Zgroup benzene ring of Z-Arg-Leu-Phe-H could fit into the space occupied by the P4 phenylalanine ring of chymostatin. The structure of chymostatin-SGPA was modified to give Z-ArgLeu-Phe-H-SGPA. These two structures were also minimized. The main chain of chymotrypsin is indicated by the shaded spheres; the interaction between the P1 phenylalanine residue of the inhibitor and the specificity pocket of chymotrypsin is clear.
trypsin. Of these, chymostatin-chymotrypsin alone contains the interaction between the N-terminal carboxy group of the inhibitor and the ammonium group of Lys-175, which improved binding (Fig. 5 ). Fig. 6 shows the docked and minimized chymostatinchymotrypsin structure in greater detail. The N-terminal carboxy group sits in a cleft formed by residues 216-218 and Trp-172. Lys-175 can be manipulated to within 2.0 A of this acidic group.
The CO2--NH3I interaction is arrowed. This interaction is not present in the other three structures owing to the absence of the 170-175 loop backbone for hydrogen-bonding to the enzyme and the Nterminal P4 carboxy group, and would avoid the synthetically troublesome arginine residue, which only contributes marginally to inhibition. The mixed inhibition of chymotrypsin by chymostatin may be due to the resemblance of the N-terminal phenylalanine to the hydrolysis product resulting in pseudo-product inhibition at a non-competitive site. This is possibly the same site for non-competitive inhibition observed by Smith & Hansch (1973) for hydrophobic molecules with ionic substituents. Whatever is responsible for this non-competitive inhibition is clearly not present in SGPA.
One of the phenylalanine aldehyde inhibitors examined in this study, X-Val-Phe-H, has been synthesized by another group (and termed MD 28170) and is reported to be an effective inhibitor of calpain (Medhi et al., 1988 ) and a weak inhibitor ofchymotrypsin (54 /M; Medhi, 1991) . Our data yield a K1 of 20 #M for this interaction, but the assay conditions are not identical. MS 28170 is thought to be a cell-penetrant inhibitor and thus offers an opportunity for inhibition in vivo of intracellular proteolysis. We expect that some of our analogues might also be sufficiently hydrophobic to be cell-permeant and thus may also find utility in such applications. Indeed, our data on inhibition of hepatocyte (Grinde et al., 1983; Place et al., 1987) and muscle (Mulligan et al., 1985) proteolysis lend weight to this argument.
